Physician profile
Jonathan A Weeks
NPI 1649364803
$3,557.62
in general payments reported to CMS, 2019-2025
32 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.22 · 2021: $93.18 · 2022: $2,560 · 2023: $270 · 2024: $334 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,546.04 | 2021-2025 | Ubrelvy, Vraylar |
| Inspire Medical Systems, INC. | $73.52 | 2024 | Inspire |
| Abbott Laboratories | $69.07 | 2022-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $57.02 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $56.97 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $51.97 | 2021-2023 | |
| Astellas Pharma US INC | $51.13 | 2022-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $48.95 | 2024-2025 | |
| Pfizer INC. | $47.00 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.46 | 2022 | |
| Merck Sharp & Dohme LLC | $40.57 | 2023-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Lundbeck LLC | $38.64 | 2024-2025 | Rexulti |
| Baxter Healthcare | $37.21 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Amgen INC. | $35.56 | 2024-2025 | Evenity, Prolia |
| Indivior INC. | $29.39 | 2024 | Sublocade |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $26.07 | 2022-2025 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $24.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $23.95 | 2023 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.36 | 2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $22.16 | 2022 | |
| Kyowa Kirin, INC. | $20.64 | 2024 | Nourianz |
| Horizon Therapeutics Plc | $20.07 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $19.41 | 2022 | |
| Dynavax Technologies Corporation | $18.74 | 2022 | |
| Glaxosmithkline, LLC. | $18.49 | 2024 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $18.35 | 2022 | |
| Cranial Technologies, INC | $18.05 | 2023 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $17.07 | 2025 | Trintellix |
| Acadia Pharmaceuticals INC | $17.02 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.28 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.